Home › Research › Treatments
The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial
Li M, Lyu JH, Zhang Y, Gao ML, Li WJ, Ma X.. Medicine, 2017-12-01
Topic: Amyloid, tau and blood-test diagnosis
Introduction Alzheimer disease (AD) is one of the most common diseases among the older adults. Currently, various nonpharmacological interventions are used for the treatment of AD. Such as reminiscence therapy is being widely used in Western countries. However, it is often used as an empirical application in China; the evidence-based efficacy of reminiscence therapy in AD patients remains to be determined. Therefore, the aim of this research is to assess the effectives of reminiscence therapy for Chinese elderly. Methods and analysis This is a randomized parallel-design controlled trial. Mild and moderate AD patients who are in the Beijing Geriatric Hospital, China will be randomized into control and intervention groups (n = 45 for each group). For the intervention group, along with conventional drug therapy, participants will be exposed to a reminiscence therapy of 35 to 45 minutes, 2 times/wk for 12 consecutive weeks. Patients in the control group will undergo conventional drug therapy only. The primary outcome measure will be the differences in Alzheimer disease Assessment Scale-Cognitive Section Score. The secondary outcome measures will be the differences in the Cornell scale for depression in dementia, Neuropsychiatric Inventory score, and Barthel Index scores at baseline, at 4 and 12 weeks of treatment, and 12 weeks after treatment. Ethics and dissemination The protocols have been approved by the ethics committee of Beijing Geriatric Hospital of China (approval no. 2015-010). Findings will be disseminated through presentation at scientific conferences and in academic journals. Trial registration Chinese Clinical Trial Registry identifier ChiCTR-INR-16009505.
Key findings
- The primary outcome measure will be the differences in Alzheimer disease Assessment Scale-Cognitive Section Score.
- The secondary outcome measures will be the differences in the Cornell scale for depression in dementia, Neuropsychiatric Inventory score, and Barthel Index scores at baseline, at 4 and 12 weeks of treatment, and 12 weeks after treatment.
- Ethics and dissemination The protocols have been approved by the ethics committee of Beijing Geriatric Hospital of China (approval no. 2015-010).
- Findings will be disseminated through presentation at scientific conferences and in academic journals.
- Trial registration Chinese Clinical Trial Registry identifier ChiCTR-INR-16009505.
Why it matters
This is a protocol for testing reminiscence therapy added to usual drug therapy in mild-to-moderate Alzheimer's disease. No results are reported, so its effect on cognition or other outcomes is not yet known.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants45
- Evidence strengthHigh
How this study scored 54/100
Published in a peer-reviewed journal, and it is a randomised controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Medicine) |
| Journal's citation record | 3 / 4 | Medicine: journal h-index 285 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomised controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 1 / 4 | 45 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 1 / 2 | Randomised (as stated in the record) |
| Times cited | 2 / 7 | Cited 11 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 11 year(s) since 2017 |
| Impact for its field and year | 1 / 6 | Cited 0.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Xin Ma: h-index 38 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Capital Medical University: institution h-index 643 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29390538) |
| Free to read | 2 / 2 | Free to read |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
APA 7th
Li, M., Lyu, J. H., Zhang, Y., Gao, M. L., Li, W. J., & Ma, X. (2017). The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial. Medicine. https://doi.org/10.1097/md.0000000000009381
Vancouver
Li M, Lyu JH, Zhang Y, Gao ML, Li WJ, Ma X. The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial. Medicine. 2017. doi:10.1097/md.0000000000009381. PMID: 29390538.
BibTeX
@article{li2017-29390538,
author = {Li, M. and Lyu, J. H. and Zhang, Y. and Gao, M. L. and Li, W. J. and Ma, X.},
title = {{The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial}},
journal = {Medicine},
year = {2017},
doi = {10.1097/md.0000000000009381},
pmid = {29390538},
url = {https://doi.org/10.1097/md.0000000000009381}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.